Search results
Showing 1231 to 1245 of 1280 results for long term conditions
Digital services to enable easier access to weight management support
Four digital programmes can be used to help the NHS deliver specialist weight management services to support the use of medication in England, NICE has said in draft guidance.
NICE’s priority is to get the best care to patients fast while ensuring value for the taxpayer.
Unpaid carers should be offered advice and support, says NICE
NICE has today published a new quality standard aimed at improving the wellbeing of adults who provide unpaid care for people over 16 years old.
Updated tuberculosis guidelines will help target most vulnerable
Updated tuberculosis (TB) guidelines call for greater education and prevention to help target people from socially deprived backgrounds who are most vulnerable to contracting the infection.
NICE's support for rebuilding capacity in non-COVID health services
Director of our Centre for Guidelines, Paul Chrisp, discusses how NICE can help the NHS and wider care sector restore services most affected by the COVID-19 pandemic
A project to improve care for older people in Wakefield has led to significant reductions in hospital admissions, attendances in A&E and ambulance call outs.
New agreement means NICE recommends combination treatment for some lymphoma patients
Hundreds of people with a form of blood cancer will benefit from a new treatment following the publication of draft guidance by NICE.
Around 105,000 people with type 1 diabetes could benefit from NICE’s draft recommendation
NICE draft guidance does not recommend risdiplam for treating spinal muscular atrophy
NICE has today (2 June 2021) published draft guidance for public consultation which does not recommend risdiplam (also called Evrysdi and made by Roche) for treating the rare genetic disorder spinal muscular atrophy (SMA).
NICE has today (20 August 2021) issued final draft guidance which now recommends sapropterin (also called Kuvan and made by BioMarin) as an option for treating phenylketonuria (PKU) in pregnant women until they give birth as well as for treating the condition in people until they turn 22.
NICE final draft guidance approves life-changing gene therapy for treating spinal muscular atrophy
A new and potentially curative one-off gene therapy for babies with the rare genetic disorder spinal muscular atrophy (SMA) is set to become the most expensive treatment ever approved by NICE.
Local government can improve the health and wellbeing of their communities, and save money in the long-term, by encouraging people to be more physically active, says NICE.
Today (Thursday 29 November), NICE opens a public consultation on its preliminary recommendations on the NHS use of the drug, pirfenidone (known commercially as Esbriet). The draft guidance assesses whether it should be recommended for use in people who have the lung condition, idiopathic pulmonary fibrosis.
NICE does not recommend elusulfase alfa for NHS use following evaluation of new evidence
NICE has today (12 November 2021) published draft guidance for public consultation which does not recommend elosulfase alfa (also called Vimizin and made by BioMarin) for the treatment of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome).
NICE has today (10 November 2020) published its draft updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS).